Despite CD133-positive cells apparently may have chemoradiation susceptibility, this data is consistent with the results that the expression CD133-positive cells in pancreatic cancer without NACRT related to poor clinical outcome [12, 13]. This evidence concerns the gene PROM1 and pancreatic neoplasm.